Simultaneous Determination of Av-133 in Rat Brain and Blood by Microdialysis Combined with Lc-Ms/Ms

Jinping Qiao,Xue Zhou,Lin Zhu,Hank Kung,Wei Yin
2011-01-01
Abstract:226 Objectives 9-[18F]fluoropropyl-(+)-dihydrotetrabenazine ([18F]AV-133) is an excellent VMAT2 ligand for diagnosis of Parkinson’s diseases. The purpose of this study is to determine the penetration of AV-133 across the BBB by developing a quantitative LC-MS/MS method. Methods The blood microdialysis probe was implanted into the jugular vein and the brain probe was inserted in striatum. Samples of microdialysates were collected simultaneously from blood and brain after the i.v. administration of 5 mg/kg non-radiolabeled and [18F]AV-133. A simultaneous determination of non-radiolabeled AV-133 and [18F]AV-133 in samples of rat blood and brain using microdialysis technique was evaluated. Results The penetration of AV-133 across the BBB in rats was studied by microdialysis combined with LC-MS/MS. This method is sensitive and reliable. The calibration curves were linear over the range of 5-1000ng/mL for AV-133 with a coefficient of determination >0.995. The intra-day and inter-day relative standard deviations were less than 10% (n=5). The concentration-time profiles of AV-133 in blood and brain were obtained, and the pharmacokinetic data were calculated. The blood-to-brain distribution ratio was defined by dividing the area under concentration (AUC) ratio of AUCbrain/AUCblood. Conclusions A LC-MS/MS method was useful in determining concentration-time profiles and pharmacokinetic data. The brain penetration of [18F]AV-133 under a carrier-added condition after a single iv injection is comparable to that observed for the no-carrier-added experiment. Research Support This work was supported by the National 973 Program (2006CB500705) and the National 863 Program(2006AA02A408), China
What problem does this paper attempt to address?